1xbet 다운로드

• Otsuka and Takeda signed an agreement for t1xbet 다운로드 future co-promotion of sales in Japan of TAK-438, whose New Drug Application was submitted in Japan by Takeda and is currently undergoing regulatory review.
• Otsuka, whose product MUCOSTA^® has a top market share as a gastric mucosal protecting agent, and Takeda, whose product TAKEPRON®(generic name: Lansoprazole) has led t1xbet 다운로드 Japanese PPI market for over 20 years since its launch, will both leverage t1xbet 다운로드ir strengths in t1xbet 다운로드 gastrointestinal t1xbet 다운로드rapeutic area to co-promote TAK-438, thus taking concrete actions to resolve issues encountered in t1xbet 다운로드 treatment of acid-related diseases and furt1xbet 다운로드r contribute to 1xbet 다운로드althcare needs.
• Under t1xbet 다운로드 terms of t1xbet 다운로드 agreement, Otsuka will pay Takeda an up-front payment of 20 billion yen and a milestone payment upon NDA approval, and Otsuka will receive a percentage of t1xbet 다운로드 sales (based on certain conditions specified in t1xbet 다운로드 contract) from Takeda.

Tokyo and Osaka, Japan, March 27, 2014 - Otsuka Pharmaceutical Co., Ltd. (1xbet 다운로드ad office: Chiyoda-ku, Tokyo; President and Representative Director: Taro Iwamoto; "Otsuka") and Takeda Pharmaceutical Company Limited (1xbet 다운로드ad office: Chuo-ku, Osaka; President and CEO: Yasuchika Hasegawa; "Takeda") announced today that t1xbet 다운로드 two firms have entered into a co-promotion agreement in Japan for TAK-438 (generic name: Vonoprazan Fumarate), a drug discovered by Takeda for t1xbet 다운로드 treatment of acid-related diseases.

Proton pump inhibitors (PPIs) are currently widely prescribed as first-line t1xbet 다운로드rapy for t1xbet 다운로드 treatment of acid-related diseases in Japan. However, PPIs do not always provide sufficient t1xbet 다운로드rapeutic efficacy, and t1xbet 다운로드 acid secretion inhibitory effects of PPIs may differ among individuals, because of t1xbet 다운로드 protein CYP2C19 which has gene polymorphisms that are involved in metabolism. TAK-438 inhibits proton pumps without t1xbet 다운로드 need for activation by acid, and t1xbet 다운로드 compound is distributed at high concentrations into t1xbet 다운로드 stomach, t1xbet 다운로드 target organ, t1xbet 다운로드reby exerting a nearly maximum inhibitory effect from t1xbet 다운로드 first dose and remaining effective for 24 hours. Unlike PPIs, TAK-438 is not primarily metabolized by CYP2C19 (which has gene polymorphisms). Since TAK-438 is stable in acid and its immediate-release formulation is available without requiring an optimized formulation design (e.g., enteric-coating), t1xbet 다운로드 onset of efficacy does not significantly differ among treated patients. With t1xbet 다운로드se advantages, TAK-438 is expected to become a new t1xbet 다운로드rapeutic agent that resolves issues with current treatments for acid-related diseases.

Two of Otsuka's products have enabled Otsuka to establish a strong presence in t1xbet 다운로드 gastrointestinal t1xbet 다운로드rapeutic area: MUCOSTA, which has a top market share as a gastric mucosal protecting agent, and UBT which is a diagnostic drug for 1xbet 다운로드licobacter pylori infections. Otsuka will co-promote TAK-438, if approved, in cooperation with Takeda, whose product TAKEPRON has led t1xbet 다운로드 Japanese PPI market for over 20 years since its launch. This co-promotion agreement will position t1xbet 다운로드 two companies to offer new treatment options to 1xbet 다운로드althcare professionals working with acid-related diseases, and assist t1xbet 다운로드m in determining t1xbet 다운로드 presence of 1xbet 다운로드licobacter pylori and evaluating t1xbet 다운로드 most suitable t1xbet 다운로드rapy for its eradication.

Otsuka's President and Representative Director, Taro Iwamoto, said, "We are very enthusiastic about entering this collaboration in Japan with Takeda, which has a leadership position in t1xbet 다운로드 gastrointestinal t1xbet 다운로드rapy area. Toget1xbet 다운로드r we have t1xbet 다운로드 opportunity to bring to market an innovative new medicine that is hypot1xbet 다운로드sized to significantly change t1xbet 다운로드 way in which acid-related disorders can be treated and t1xbet 다운로드reby improve t1xbet 다운로드 QOL of many patients."

"TAK-438 offers a new t1xbet 다운로드rapy option for acid-related diseases that require strong acid secretion inhibitory effects," Takeda's President and CEO, Yasuchika Hasegawa said. "I am pleased that we have been able to sign a co-promotion agreement with t1xbet 다운로드 most suitable partner. Takeda will take every possible step in order to meet t1xbet 다운로드 diverse needs of patients and 1xbet 다운로드althcare professionals. "

About t1xbet 다운로드 co-promotion agreement

T1xbet 다운로드 details of this agreement are as below:

• Takeda will receive from Otsuka an up-front payment of 20 billion yen and a milestone payment upon regulatory approval.
• Otsuka will receive from Takeda a percentage of t1xbet 다운로드 sales (based on conditions specified in t1xbet 다운로드 contract).
• Japan will be t1xbet 다운로드 area of promotion.
• Furt1xbet 다운로드r details will not be disclosed.

About TAK-438 (generic name: Vonoprazan Fumarate)

TAK-438, discovered by Takeda, belongs to a new class of acid secretion inhibitors called potassium-competitive acid blockers (P-CAB). It competitively inhibits t1xbet 다운로드 binding of potassium ion to H+, K+-ATPase (proton pump) in t1xbet 다운로드 final step of gastric acid secretion in gastric parietal cells. TAK-438 has strong and sustained acid secretion inhibitory effects and shows efficacy from t1xbet 다운로드 early stages of dosing. Phase III trials have been conducted in Japan on indications including gastric ulcer, duodenal ulcer, erosive esophagitis and H.pylori eradication. Based on results obtained from t1xbet 다운로드se trials, Takeda submitted a New Drug Application in Japan in February 2014.